Slovenian recommendations for the management of chronic myeloid leukaemia

  • Irena Preložnik Zupan Klinični oddelek za hematologijo Univerzitetni klinični center Zaloška 7 1525 Ljubljana
  • Karla Rener Klinični oddelek za hematologijo Univerzitetni klinični center Zaloška 7 1525 Ljubljana
  • Helena Podgornik Klinični oddelek za hematologijo Univerzitetni klinični center Zaloška 7 1525 Ljubljana
  • Matjaž Sever Klinični oddelek za hematologijo Univerzitetni klinični center Zaloška 7 1525 Ljubljana
  • Martina Fink Klinični oddelek za hematologijo Univerzitetni klinični center Zaloška 7 1525 Ljubljana
  • Mateja Grat SB Celje Oblakova 5 3000 Celje
  • Tadej Pajič Klinični oddelek za hematologijo Univerzitetni klinični center Zaloška 7 1525 Ljubljana
DOI: https://doi.org/10.6016/ZdravVestn.2713
Keywords: chronic myeloid leukemia, chronic phase, accelerated phase, blast phase, milestones of the treatment

Abstract

The paper presents recommendations for the management of patients with chronic myeloid leukaemia. Clinical manifestations, diagnostics, treatment and monitoring of treatment are presented.

Downloads

Download data is not yet available.

References

Preložnik Zupan I. Kronična mieloična levkemija. In: Košnik M, ur. Interna medicina: univerzitetni učbenik. 5. izd. Ljubljana: Littera picta; Slovensko medicinsko društvo; 2017.

Apperley JF. Chronic myeloid leukaemia. Lancet. 2015 Apr;385(9976):1447–59. https://doi.org/10.1016/S0140-6736(13)62120-0 PMID:25484026

Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999 Apr;340(17):1330–40. https://doi.org/10.1056/NEJM199904293401706 PMID:10219069

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun;109(11):4686–92. https://doi.org/10.1182/blood-2006-11-055186 PMID:17317858

Preložnik Zupan I, Pajič T, Glaser M, Grmek Zemljič T, Grat M, Fikfak N, et al. Uspešnost zdravljenja KML v Sloveniji v obdobju inhibitorjev tirozinske kinaze. Zdrav Vestn Suppl. 2012;81:II56-64.

Preložnik Zupan I, Pajic T, Glaser M, Grmek-Zemljic T, Grat M, Fikfak N et al. Epidemiološki podatki bolnikov s kronično mieloično levkemijo v Sloveniji. Zdrav Vestn. 2008;77(1):51–5.

Van Etten RA. Clinical manifestations and diagnosis of chronic myeloid leukemia [2017 Sept]. Available from: https://www.uptodate.com/

Negrin RS, Schiffer CA. Overview of the treatment of chronic myeloid leukemia [2017 Sept]. Available from: https://www.uptodate.com./

Združenje hematologov Slovenije, Preložnik Zupan I, Pajič T. Smernice za odkrivanje in zdravljenje kronične mieloične levkemije. Zdrav Vestn Suppl. 2008;77:I5–10.

Leukemia CM. version 2.2017, National Comprehensive Cancer Network (NCCN). [2017 Sept]. Available from: http://www.nccn.org/

Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 Jun;127(22):2742–50. https://doi.org/10.1182/blood-2016-01-690230 PMID:27006386

Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res. 2008 Apr;32(4):579–85. https://doi.org/10.1016/j.leukres.2007.08.017 PMID:17928051

Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009 Feb;113(8):1619–30. https://doi.org/10.1182/blood-2008-03-144790 PMID:18827185

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014 May;89(5):547–56. https://doi.org/10.1002/ajh.23691 PMID:24729196

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug;122(6):872–84. https://doi.org/10.1182/blood-2013-05-501569 PMID:23803709

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544 PMID:27069254

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJ, Hjorth-Hansen H et al.; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28 suppl_4:iv41–51.

Söderlund S, Dahlén T, Sandin F, Olsson-Strömberg U, Creignou M, Dreimane A et al. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register. Eur J Haematol. 2017 Jan;98(1):57–66. https://doi.org/10.1111/ejh.12785 PMID:27428357

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984 Apr;63(4):789–99. PMID:6584184

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al.; Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998 Jun;90(11):850–8. https://doi.org/10.1093/jnci/90.11.850 PMID:9625174

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul;118(3):686–92. https://doi.org/10.1182/blood-2010-12-319038 PMID:21536864

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016 Jan;30(1):48–56. https://doi.org/10.1038/leu.2015.261 PMID:26416462

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al.; SAKK and the German CML Study Group. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015 Dec;94(12):2015–24. https://doi.org/10.1007/s00277-015-2494-9 PMID:26385387

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999–1003. https://doi.org/10.1038/leu.2015.29 PMID:25652737

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al.; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep;108(6):1809–20. https://doi.org/10.1182/blood-2006-02-005686 PMID:16709930

Drucker BJ, Guilhot F, O’Brien SG. Five-year follow-up of imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. 2006;355:2404–17.

Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011 Aug;118(5):1208–15. https://doi.org/10.1182/blood-2010-12-326405 PMID:21562040

Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012 Nov;205(11):563–71. https://doi.org/10.1016/j.cancergen.2012.09.003 PMID:23111092

O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar;348(11):994–1004. https://doi.org/10.1056/NEJMoa022457 PMID:12637609

Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb;119(5):1123–9. https://doi.org/10.1182/blood-2011-08-376087 PMID:22160483

Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197–203. https://doi.org/10.1038/leu.2012.134 PMID:22699418

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L et al.; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015 Jul;126(1):42–9. https://doi.org/10.1182/blood-2015-01-617993 PMID:25918346

Baccarani M, Pane F, Rosti G, Russo D, Saglio G. Chronic myeloid leukemia: room for improvement? Haematologica. 2017 Jul;102(7):1131–3. https://doi.org/10.3324/haematol.2017.166280 PMID:28655808

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016 Mar;108(7):djw003. https://doi.org/10.1093/jnci/djw003 PMID:26944912

Kralj E, Žakelj S, Trontelj J, Pajič T, Preložnik Zupan I, Černelč P et al. Monitoring of imatinib targeted delivery in human leukocytes. Eur J Pharm Sci. 2013 Sep;50(1):123–9. https://doi.org/10.1016/j.ejps.2013.04.026 PMID:23643738

Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011 May;35(5):626–30. https://doi.org/10.1016/j.leukres.2010.10.017 PMID:21095002

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep;26(3):428–42. https://doi.org/10.1016/j.ccr.2014.07.006 PMID:25132497

Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct;25(5):1025–48. https://doi.org/10.1016/j.hoc.2011.09.003 PMID:22054733

Povzetek glavnih značilnosti zdravila Tasigna [2017 Oct]. Available from: https://ec.europa.eu/health/documents/community-register/2017/20170524137917/anx_137917_sl.pdf

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648–71. https://doi.org/10.1038/leu.2016.104 PMID:27121688

Published
2018-04-21
How to Cite
1.
Preložnik Zupan I, Rener K, Podgornik H, Sever M, Fink M, Grat M, Pajič T. Slovenian recommendations for the management of chronic myeloid leukaemia. TEST ZdravVestn [Internet]. 21Apr.2018 [cited 26Apr.2024];87(3-4):191-12. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2713
Issue
Vol 87 No 3-4 (2018): March-April
Section
Professional Article

Copyright (c) 2018 Slovenian Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.